Edition:
United States

Progenics Pharmaceuticals Inc (PGNX.OQ)

PGNX.OQ on NASDAQ Stock Exchange Global Select Market

8.86USD
5 Dec 2016
Change (% chg)

-- (--)
Prev Close
$8.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
372,116
52-wk High
$9.20
52-wk Low
$3.64

Latest Key Developments (Source: Significant Developments)

Progenics Pharmaceuticals Q2 loss per share $0.08
Thursday, 4 Aug 2016 07:30am EDT 

Progenics Pharmaceuticals Inc : Q2 loss per share $0.08 . Progenics Pharmaceuticals announces second quarter 2016 financial and business results . Q2 earnings per share view $-0.13 -- Thomson Reuters I/B/E/S .On track to initiate phase 2/3 trial for PYL(TM) imaging agent and phase 1 trial for 1095 this year.  Full Article

Valeant and Progenics announce FDA approvals for relistor
Tuesday, 19 Jul 2016 06:04pm EDT 

Progenics Pharmaceuticals Inc : Valeant expects to commence sales of relistor tablets in U.S. in Q3 of 2016 . Valeant and Progenics announce FDA approves relistor tablets for the treatment of opioid-induced constipation in adults with chronic non-cancer pain .FDA has approved relistor (methylnaltrexone bromide) tablets for treatment of opioid-induced constipation.  Full Article

Progenics Pharmaceuticals signs commercial license agreement with Selexis SA
Tuesday, 21 Jun 2016 08:45am EDT 

Press Release : Under agreement, progenics will have use of Selexis CHO-M cell line and sure technology platform . Financial terms were not disclosed .Progenics Pharmaceuticals, Inc. Signs commercial license agreement with Selexis SA for use of proprietary cell line and suretechnology platform.  Full Article

Progenics Pharmaceuticals Inc announces the appointment of Patrick Fabbio as CFO
Monday, 16 Nov 2015 07:30am EST 

Progenics Pharmaceuticals Inc:Says appointment of Patrick Fabbio as Chief Financial Officer.  Full Article

Progenics Pharmaceuticals makes tender offer for in Exini Diagnostics
Tuesday, 13 Oct 2015 02:29am EDT 

Exini Diagnostics AB:Progenics Pharmaceuticals Inc has on Oct 13 announced offer to tender all of shares in Exini for a consideration of 3.15 Swedish crowns per share.Says total value, based on 18,381,081 issued shares in Exini, amounts to about 57.9 million Swedish crowns.Offer price represents a premium of about 93 percent compared with EXINI's closing price of 1.63 crows per share on NASDAQ First North Stockholm on Oct. 12.Board decided to unanimously recommend that shareholders accept offer.  Full Article

Valeant Pharmaceuticals International Inc and Progenics Pharmaceuticals Inc announce FDA acceptance of NDA submission for oral RELISTOR
Tuesday, 8 Sep 2015 08:00am EDT 

Valeant Pharmaceuticals International Inc and Progenics Pharmaceuticals Inc:Says that U.S. Food and Drug Administration (FDA) has accepted for review Valeant's New Drug Application for RELISTOR (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.Says FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of April 16, 2016.  Full Article

Progenics Pharmaceuticals Inc announces exclusive worldwide licensing agreement with Johns Hopkins University
Tuesday, 4 Aug 2015 08:30am EDT 

Progenics Pharmaceuticals Inc:Announces exclusive worldwide licensing agreement with johns hopkins university.For agent to image prostate cancer using pet scan.Announces exclusive worldwide licensing agreement with Johns Hopkins University for agent to image prostate cancer using pet scan.Says financial terms of the transaction were not disclosed.  Full Article

Progenics Pharmaceuticals Inc announces breakthrough therapy designation for azedra in pheochromocytoma and paraganglioma
Tuesday, 28 Jul 2015 08:30am EDT 

Progenics Pharmaceuticals Inc:Says U.S Food and Drug Administration (FDA) has designated Azedra as breakthrough therapy.For treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma and paraganglioma.Azedra is currently being evaluated in a pivotal Phase 2b trial, which is being conducted under special protocol assessment agreement (SPA), and has received orphan drug and fast track designations from FDA.  Full Article

Progenics Pharmaceuticals, Inc. announces Plans to Move Forward With 1404 Phase 3 Trial
Tuesday, 7 Jul 2015 08:30am EDT 

Progenics Pharmaceuticals, Inc:Says plans to move forward with 1404 phase 3 trial.Says Progenics expects the phase 3 trial to commence by the end of this year.  Full Article

Progenics Pharmaceuticals relaunches pivotal trial of AZEDRA in Pheochromocytoma
Friday, 23 Jan 2015 08:00am EST 

Progenics Pharmaceuticals Inc:Says it has dosed the first subject in the resumed pivotal Phase 2 clinical study of Azedra((tm))in patients with malignant pheochromocytoma and paraganglioma.Trial is being conducted under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration.Study is designed to evaluate the efficacy and safety of the administration of two therapeutic doses of Azedra in patients with malignant relapsed/refractory pheochromocytoma or paraganglioma, ultra-orphan cancers with limited treatment options.Primary objective of the study is to determine the clinical benefit of Azedra based on the proportion of study participants with a reduction of all antihypertensive medication by at least 50% for at least six months.Azedra has received Orphan Drug and Fast Track designations from the FDA.  Full Article